Literature DB >> 16894514

The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.

David L Paterson1.   

Abstract

Isolates of Pseudomonas aeruginosa or Acinetobacter species that are resistant to all, or almost all, commercially available antibiotics are now prevalent worldwide. Typically, these strains are recovered from patients in intensive care units who have ventilator-associated pneumonia. "Panresistant" strains can be defined as strains that are resistant to all beta -lactam and quinolone antibiotics recommended as empirical therapy for ventilator-associated pneumonia. These strains are well adapted to the hospital environment--molecular epidemiological studies have frequently revealed that only 1 or 2 clones caused outbreaks in intensive care units. However, panresistant strains may also be selected by antibiotic use. Given the lack of antibiotic options to treat infection with panresistant strains, enhanced surveillance for these organisms is necessary at unit-specific, institutional, and national levels.

Entities:  

Mesh:

Year:  2006        PMID: 16894514     DOI: 10.1086/504476

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  85 in total

1.  Antibacterial Mechanism of (-)-Nortrachelogenin in Escherichia coli O157.

Authors:  Heejeong Lee; Young Rae Ji; Zae Young Ryoo; Myung-Sook Choi; Eun-Rhan Woo; Dong Gun Lee
Journal:  Curr Microbiol       Date:  2015-09-29       Impact factor: 2.188

2.  In-silico modeling of a novel OXA-51 from β-lactam-resistant Acinetobacter baumannii and its interaction with various antibiotics.

Authors:  Vishvanath Tiwari; Isha Nagpal; Naidu Subbarao; Rajeswari R Moganty
Journal:  J Mol Model       Date:  2012-01-22       Impact factor: 1.810

3.  Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.

Authors:  Oscar Cirioni; Roberto Ghiselli; Carmela Silvestri; Wojciech Kamysz; Fiorenza Orlando; Federico Mocchegiani; Fabio Di Matteo; Alessandra Riva; Jerzy Lukasiak; Giorgio Scalise; Vittorio Saba; Andrea Giacometti
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

Review 4.  Acinetobacter pneumonia: a review.

Authors:  Joshua D Hartzell; Andrew S Kim; Mark G Kortepeter; Kimberly A Moran
Journal:  MedGenMed       Date:  2007-07-05

Review 5.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

6.  Colistin therapy for multidrug-resistant Gram-negative infection: clinical outcome and risk factors.

Authors:  Y H Jun; S J Jeun; S H Kang; H J Choi
Journal:  Infection       Date:  2013-09-15       Impact factor: 3.553

7.  Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children.

Authors:  Meltem Polat; Soner Sertan Kara; Anıl Tapısız; Hasan Tezer; Gökhan Kalkan; Anıl Dolgun
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

8.  The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis.

Authors:  S E Blair; N N Cokcetin; E J Harry; D A Carter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-10       Impact factor: 3.267

9.  Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.

Authors:  Shawn R Lockhart; Murray A Abramson; Susan E Beekmann; Gale Gallagher; Stefan Riedel; Daniel J Diekema; John P Quinn; Gary V Doern
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

10.  Variation in antibiotic susceptibility of uropathogens by age among ambulatory pediatric patients.

Authors:  Jessina C McGregor; Yennie Quach; David T Bearden; David H Smith; Susan E Sharp; Judith A Guzman-Cottrill
Journal:  J Pediatr Nurs       Date:  2013-09-30       Impact factor: 2.145

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.